Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Capital Expenditures (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Capital Expenditures for 13 consecutive years, with $8000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 95.79% to $8000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $213000.0 through Dec 2025, down 35.84% year-over-year, with the annual reading at $42000.0 for FY2025, 87.35% down from the prior year.
  • Capital Expenditures for Q4 2025 was $8000.0 at Theravance Biopharma, down from $190000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $1.8 million in Q1 2021, with the low at -$57000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $400352.9, with a median of $190000.0 recorded in 2024.
  • The sharpest move saw Capital Expenditures tumbled 105.49% in 2022, then soared 653.98% in 2023.
  • Over 5 years, Capital Expenditures stood at $444000.0 in 2021, then plummeted by 40.09% to $266000.0 in 2022, then skyrocketed by 154.51% to $677000.0 in 2023, then plummeted by 71.94% to $190000.0 in 2024, then crashed by 95.79% to $8000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $8000.0, $190000.0, and $15000.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.